Loss or abnormal expression of the MMR proteins MLH1, MSH2, MSH6 and PMS2, assessed by immunohistochemistry, is standard practice in many pathology laboratories and is used to help identify LS cancers along with MSI typing of tumour DNA [24–26] (Fig. 2). The gene discussed is MLH1; the disease is neoplasm.